journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Investigational Drugs

journal
https://www.readbyqxmd.com/read/27894193/currently-used-and-investigational-drugs-for-cushing%C3%A2-s-disease
#1
Denis Ciato, Aizhar G Mumbach, Marcelo Paez-Pereda, Günter K Stalla
Cushing's disease (CD) is caused by a corticotroph adenoma of the pituitary gland that secretes excess adrenocorticotropic hormone (ACTH) causing increased morbidity and mortality. Surgery is the treatment of choice, but is not always successful. Alternatives include radiotherapy, adrenal surgery, and pharmaceutical therapy. The latter is increasingly gaining momentum due to the recent development of compounds that reduce hypercortisolaemia or its symptoms, acting through different mechanisms. Areas covered: In this article, the authors provide a complete overview of the treatment options for Cushing´s disease, including adrenal-directed, tumor-targeted, and peripheral therapies that are currently used or in development, and discuss their potential advantages and limitations...
November 29, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27892725/investigational-serine-threonine-kinase-inhibitors-against-prostate-cancer-metastases
#2
Claudio Festuccia
INTRODUCTION: Androgen deprivation therapy (ADT) is used as first therapeutic approach in prostate cancer (PCa) although castration resistant disease (CRPC) develops with high frequency. CRPC is the consequence of lack of apoptotic responses to ADT. Alternative targeting of the androgen axis with abiraterone and enzalutamide, as well as taxane-based chemotherapy were used in CRPC. Serine/threonine protein kinases (STKs) regulate different molecular pathways of normal and neoplastic cells and participate to development of CRPC as well as to the progression towards a bone metastatic disease (mCRPC)...
November 28, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27885860/pioglitazone-for-the-treatment-of-alzheimer-s-disease
#3
Daniela Galimberti, Elio Scarpini
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD includes Anticholinesterase Inhibitors (AChEIs) for mild-moderate AD, and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly influencing the progression of the disease. Pioglitazone (AD4833) is an insulin sensitizer of the thiazolidinedione class of nuclear Peroxisome-Proliferator Activated Receptor γ (PPARγ) agonists. It binds to PPARγ, affecting gene transcription and reducing inflammation...
November 25, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27841017/investigational-drugs-targeting-the-prostaglandin-e2-signaling-pathway-for-the-treatment-of-inflammatory-pain
#4
Sabine Grösch, Ellen Niederberger, Gerd Geisslinger
Non-steroidal anti-inflammatory drugs (NSAID) are the most commonly used drugs for the treatment of pain, inflammation and fever. Although they are effective for a huge number of users, their analgesic properties are not sufficient for several patients and the occurrence of side effects still constitutes a big challenge during long term therapy. Areas covered: This review gives an overview about the first and second generations of NSAIDs (COX1/2 non-selective, COX-2 selective), and their main side effects which gave still an urgent need for safer drugs and for the establishment of novel treatment strategies (improved safety, tolerability, patient convenience)...
November 20, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27791405/experimental-and-early-investigational-drugs-for-angina-pectoris
#5
Islam Y Elgendy, David E Winchester, Carl J Pepine
Ischemic heart disease (IHD) is a major cause of death and disability among Western countries and angina pectoris is the most prevalent symptomatic manifestation. Strategies to improve management of chronic stable angina are a priority. Areas covered: A comprehensive review was conducted using the Medline and Cochrane databases as well as the clinical trial databases in the United States and Europe. Traditional therapies for angina will be discussed. This review particularly emphasizes investigational therapies for angina (including pharmacological agents, cell and gene based therapies, and herbal medications)...
November 14, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27838928/the-early-clinical-development-of-ebola-virus-treatments
#6
Steven B Bradfute
No abstract text is available yet for this article.
November 12, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27828719/newer-drugs-for-heart-failure-hype-or-hope
#7
Jalal K Ghali
No abstract text is available yet for this article.
November 9, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27785928/lomitapide-for-the-treatment-of-hypertriglyceridemia
#8
Amanda J Brahm, Robert A Hegele
Severe genetic forms of hypertriglyceridemia carry a risk of life-threatening pancreatitis and lack available effective treatments. Lomitapide is a microsomal triglyceride transfer protein inhibitor currently approved for treatment of homozygous familial hypercholesterolemia that may be useful in the management of severe hypertriglyceridemia. Areas covered: Published trials of lomitapide that reported plasma triglyceride response were reviewed, as was a case report of a patient with hypertriglyceridemia who was treated for 13 years with lomitapide...
November 9, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27813422/bioequivalence-safety-and-immunogenicity-of-bi-695501-an-adalimumab-biosimilar-candidate-compared-with-the-reference-biologic-in-a-randomized-double-blind-active-comparator-phase-i-clinical-study-voltaire%C3%A2-pk-in-healthy-subjects
#9
Christopher Wynne, Mario Altendorfer, Ivo Sonderegger, Lien Gheyle, Rod Ellis-Pegler, Susanne Buschke, Benjamin Lang, Deepak Assudani, Sandeep Athalye, Niklas Czeloth
Background This Phase I study (VOLTAIRE™-PK) aimed to evaluate three-way pharmacokinetic similarity (bioequivalence), safety and immunogenicity of BI 695501 (a Humira® [adalimumab] biosimilar candidate) compared with US- and EU-approved Humira in healthy male subjects. Methods Subjects (N = 327) were randomized 1:1:1 to receive one 40 mg subcutaneous dose of BI 695501, US- or EU-approved Humira; safety was assessed for 70 days. Bioequivalence was evaluated using the average bioequivalence method to test if the 90% confidence intervals (CIs) of the geometric means (BI 695501 versus US- and EU-approved Humira) for the primary endpoints were within pre-specified acceptance ranges (80-125%)...
November 4, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27771967/novel-investigational-therapies-for-treating-biliary-tract-carcinoma
#10
M Tampellini, A La Salvia, G V Scagliotti
Cholangiocarcinoma (CCA) is an epithelial cell malignancy arising from bile ducts and/or peribiliary glands. Even though it is considered as a rare neoplasm, its incidence is raising, particularly in developed countries. Prognosis is generally poor with few patients who present the inclusion criteria for surgery (the mainstay treatment for this tumour). Several genetic alterations potentially driving tumour progression have been described, representing a possible target for new compounds. Areas covered: A clinical trial search in Clinicaltrials...
November 3, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27802062/experimental-drugs-for-bipolar-psychosis
#11
Michele Fornaro, António E Nardi, Domenico De Berardis, Mauro G Carta
Psychotic features are common in bipolar disorder (BD), especially during acute mania. Even when early detected, their long-term management is difficult, essentially due to the unsatisfactory efficacy/tolerability profile of currently available treatments, thus soliciting the development of novel experimental drugs. Areas covered: Potential drug targets towards the development of experimental drugs in the treatment of bipolar psychosis are yet to be systematically characterized. Among other potential avenues, the kynurenic acid pathway may represent an intriguing opportunity...
November 1, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27771969/vinflunine-for-the-treatment-of-non-small-cell-lung-cancer
#12
C Genova, A Alama, S Coco, E Rijavec, M G Dal Bello, I Vanni, F Biello, G Barletta, G Rossi, F Grossi
Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the microtubule dynamics during cell cycle; this agent is currently available for previously treated advanced transitional cell carcinoma in Europe. The aim of this invited review is to evaluate the potential role of vinflunine for the treatment of non-small cell lung cancer (NSCLC). Areas covered: The potential role of vinflunine in NSCLC is discussed on the basis of the available data, including full papers and meeting abstracts. Relevant preclinical studies describing the pharmacological properties of vinflunine are also included...
November 1, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27797594/folate-receptor-alpha-antagonists-in-preclinical-and-early-stage-clinical-development-for-the-treatment-of-epithelial-ovarian-cancer
#13
Alice Bergamini, Simone Ferrero, Umberto Leone Roberti Maggiore, Carolina Scala, Francesca Pella, Valerio Gaetano Vellone, Micaela Petrone, Emanuela Rabaiotti, Raffaella Cioffi, Massimo Candiani, Giorgia Mangili
The prognosis of patients affected by ovarian cancer has not substantially changed in the last decades and improving survival still remains a challenge. In the promising era of "personalized therapy" several new biologic therapies are currently being investigated: in this setting, targeting the folate receptor (FR) has been considered a new potential strategy for biologic therapy. Areas covered. The aim of the current review is to summarize, giving a critical overview,promising folate receptor alpha antagonists under preclinical or early clinical development for ovarian cancer...
October 31, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27756180/investigational-histone-deacetylase-inhibitors-hdaci-in-myeloproliferative-neoplasms
#14
Prithviraj Bose, Srdan Verstovsek
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) mainly comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, primary or post-PV/ET). Therapy in PV and ET focuses on minimizing thrombosis and bleeding risk, while in MF, prolongation of survival is an important goal. Different cytoreductive agents are employed in high risk PV and ET, while the JAK inhibtior ruxolitinib is the cornerstone of therapy in MF. Histone deacetylase inhibitors (HDACi) are pleiotropic agents with diverse epigenetic and non-epigenetic actions, selectively in transformed cells...
October 31, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27748152/developments-with-investigational-janus-kinase-inhibitors-for-rheumatoid-arthritis
#15
Luca Semerano, Patrice Decker, Gaëlle Clavel, Marie-Christophe Boissier
No abstract text is available yet for this article.
October 31, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27791451/ccr5-receptor-antagonists-in-preclinical-to-phase-ii-clinical-development-for-treatment-of-hiv
#16
Michelle B Kim, Kyle E Giesler, Yesim A Tahirovic, Valarie M Truax, Dennis C Liotta, Lawrence J Wilson
The chemokine receptor CCR5 has garnered significant attention in recent years as a target to treat HIV infection largely due to the approval and success of the drug Maraviroc. The side effects and inefficiencies with other first generation agents led to failed clinical trials, prompting the development of newer CCR5 antagonists. Areas Covered: This review aims to survey the current status of "next generation" CCR5 antagonists in the preclinical pipeline with an emphasis on emerging agents for the treatment of HIV infection...
October 28, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27754718/investigational-drugs-in-dry-eye-disease
#17
Marcella Nebbioso, Valeria Fameli, Magda Gharbiya, Marta Sacchetti, Anna Maria Zicari, Alessandro Lambiase
The dry eye disease (DED) is a chronic multifactorial disorder of the tears that also involves the ocular surface, the lacrimal glands, and meibomian dysfunction. Furthermore, DED is often associated with Sjögren's syndrome (SS) and other autoimmune disorders. Sometimes, this chronic or subclinical condition is difficult to diagnose and treat, due to its heterogeneity. Areas covered: A literature search of relevant publications about treatment of DED was performed. All relevant articles published between 2011 and 2016 were identified through a computerized search for reviews and clinical trials using the Pub Med database...
October 28, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27677932/investigational-%C3%AE-synuclein-aggregation-inhibitors-hope-for-parkinson-s-disease
#18
Nóra Török, Zsófia Majláth, Levente Szalárdy, László Vécsei
The therapeutic management of Parkinson's disease (PD) is challenging and has not been fully resolved. The main challenges include motor fluctuations and levodopa-induced dyskinesia. Moreover, no disease-modifying or neuroprotective therapy is currently available. Areas covered: This review focuses on α-synuclein aggregation inhibitors and their therapeutic role in PD, with special attention to heat shock proteins, immunotherapy (active and passive), the potential of targeting the Ser129 phosphorylation site, and the antibiotic possibilities...
October 8, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27676206/monoclonal-antibodies-for-the-treatment-of-ebola-virus-disease
#19
A L Moekotte, M A M Huson, A J van der Ende, S T Agnandji, E Huizenga, A Goorhuis, M P Grobusch
To date, the management of patients with suspected or confirmed Ebolavirus disease (EVD) depends on quarantine, symptomatic management and supportive care, as there are no approved vaccines or treatments available for human use. However, accelerated by the recent large outbreak in West Africa, significant progress has been made towards vaccine development but also towards specific treatment with convalescent plasma and monoclonal antibodies. Areas covered: We describe recent developments in monoclonal antibody treatment for EVD, encompassing mAb114 and the MB-003, ZMAb, ZMapp™ and MIL-77E cocktails...
October 8, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27677828/sunitinib-for-the-treatment-of-thyroid-cancer
#20
José-Manuel Gómez-Sáez
Sunitinib is an oral oxindol derivative and a potent inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor and a multitargeted tyrosine-kinase inhibitor, which has antitumor and antiangiogenic activity due to the selective inhibition that can stabilize progressive metastatic disease. The aim of this review is to expose whether the drug could be considered as a new promising therapy compared with other tyrosine-kinase inhibitors. Areas covered: In seven open-label studies carried out with sunitinb, the drug showed its anti-tumoral activity in advanced differentiated thyroid carcinoma and in medullary thyroid carcinoma...
October 6, 2016: Expert Opinion on Investigational Drugs
journal
journal
32001
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"